Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)

The inhibition of histone deacetylase (HDAC) can induce differentiation, growth arrest, and apoptosis in cancer cells. This phase II multicenter study was undertaken to estimate the efficacy of belinostat, a potent inhibitor of both class I and class II HDAC enzymes, for the treatment of myelodyspla...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Cashen, Amanda, Juckett, Mark, Jumonville, Alcee, Litzow, Mark, Flynn, P. J., Eckardt, John, LaPlant, Betsy, Laumann, Kristina, Erlichman, Charles, DiPersio, John
Format: Artigo
Langue:Inglês
Publié: 2011
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3557843/
https://ncbi.nlm.nih.gov/pubmed/21538061
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-011-1240-1
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires